eligibility_summary
Eligibility: Adults 18–70 with untreated stage III/IV classical, CD30+ Hodgkin lymphoma, ECOG ≤2, adequate labs: ANC ≥1500/µL, platelets ≥75k/µL, Hgb ≥8 g/dL, Tbili <1.5×ULN, AST/ALT <3×ULN, Cr <2.0 mg/dL or CrCl >40 mL/min. Exclude: NLPHL/NHL, CNS disease, prior chemo/RT/immunotherapy, HIV/HBV/HCV, organ failure, LVEF <50% or major cardiac disease/MI <2 yrs, pregnant/breastfeeding, neuropathy, DLCO >25% below predicted, hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT07171827 tests BV+AVD vs ABVD as frontline therapy for advanced classical Hodgkin lymphoma. Drugs/mechanisms (type): - Brentuximab vedotin (ADC): anti‑CD30 mAb linked to MMAE, binds CD30, is internalized, releases MMAE to disrupt microtubules → G2/M arrest/apoptosis. - Doxorubicin (anthracycline): DNA intercalation, topoisomerase II inhibition, free-radical DNA damage. - Vinblastine (vinca alkaloid): inhibits tubulin polymerization/microtubules. - Dacarbazine (triazene alkylator): hepatic activation → DNA methylation/alkylation. - Bleomycin (antitumor antibiotic, ABVD arm only): induces DNA strand breaks via free radicals. Cells/pathways targeted: CD30+ Hodgkin/Reed–Sternberg cells (TNFR family/CD30 signaling), microtubule dynamics (MMAE, vinblastine), DNA replication/repair and damage response (doxorubicin, dacarbazine, bleomycin), topoisomerase II (doxorubicin).